Study for Safety and Efficiency of Therapeutic Angiogenesis for Patients With Limb Ischemia by Transplantation of Human Cord Blood Mononuclear Cell

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Samsung Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00518934
First received: August 19, 2007
Last updated: August 20, 2007
Last verified: May 2007
  Purpose

The purpose of this study is to analyze the safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cells.


Condition Intervention Phase
Ischemia
Other: Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care

Further study details as provided by Samsung Medical Center:

  Eligibility

Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:Patients with ischemic symptoms such as claudication, rest pain or nonhealing ischemic wound

  • Without evidence of improvement in response to conventional medical therapy
  • Not candidates for surgical intervention or radiologic intervention

Exclusion Criteria:

  • Malignant disease
  • More than 60 years old
  • Other significant medical conditions, including diabetes mellitus, hypertension, hyperlipidemia, etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00518934

Contacts
Contact: Dong-Ik Kim, Professor 82-2-3410-3467 dikim@skku.edu

Locations
Korea, Republic of
Samsung Medical Center, Sungkyunkwan University School of Medicine Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Dong-Ik Kim, Professor    82-2-3410-3467    dikim@skku.edu   
Sponsors and Collaborators
Samsung Medical Center
Investigators
Study Director: Dong-Ik Kim, Professor Professor of division of vascular surgery, Samsung Medical Center, Sungkyunkwan University of School of Medicine
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00518934     History of Changes
Other Study ID Numbers: 2007-04-064
Study First Received: August 19, 2007
Last Updated: August 20, 2007
Health Authority: Korea: Samsung Medical Center Institutional Review Board

Keywords provided by Samsung Medical Center:
Safety and efficiency of angiogenesis for patients with limb
ischemia by transplantation of human cord blood mononuclear
cells

Additional relevant MeSH terms:
Ischemia
Pathologic Processes

ClinicalTrials.gov processed this record on September 14, 2014